Literature DB >> 16231178

Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies.

Falko Fend1, Oliver Bock, Markus Kremer, Katja Specht, Leticia Quintanilla-Martinez.   

Abstract

Pathologic examination of trephine bone marrow (BM) biopsies plays a central role in the diagnosis and staging of haematological neoplasms and other disorders affecting haematopoiesis. Haematopathology has been profoundly influenced by the advent of molecular genetic techniques suitable for paraffin-embedded tissues, and certain applications, such as the determination of B- and T-cell clonality, belong to its standard diagnostic repertoire. Many of these molecular tests can be performed successfully with nucleic acids extracted from BM trephine biopsies, if some technical aspects specific to this template source such as various fixation and decalcification procedures are taken into consideration. The current indications for molecular BM diagnostics range from the confirmation of lymphoma involvement with gene rearrangement analysis, demonstration of tumor-specific translocations in lymphoid and chronic myeloproliferative disorders along to the detection of microorganisms or marrow involvement by soft tissue sarcomas. The availability of quantitative polymerase chain reaction techniques for the investigation of allelic imbalances and gene expression levels in paraffin-embedded material also open new avenues for research and advanced diagnostics. The molecular detection of minimal residual disease in haematological neoplasms, especially in the context of new treatment strategies, will provide future challenges. This article summarizes the current state of the art in molecular diagnostics applied to paraffin-embedded BM biopsies.

Entities:  

Mesh:

Year:  2005        PMID: 16231178     DOI: 10.1007/s00428-005-0069-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  85 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

Review 2.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

3.  How reliable is histologic examination of bone marrow trephine biopsy specimens for the staging of non-Hodgkin lymphoma? A study of hairy cell leukemia and mantle cell lymphoma involvement of the bone marrow trephine specimen by histologic, immunohistochemical, and polymerase chain reaction techniques.

Authors:  S Pittaluga; A Tierens; Y L Dodoo; J Delabie; C De Wolf-Peeters
Journal:  Am J Clin Pathol       Date:  1999-02       Impact factor: 2.493

4.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  E Olavarria; E Kanfer; R Szydlo; J Kaeda; K Rezvani; K Cwynarski; C Pocock; F Dazzi; C Craddock; J F Apperley; N C Cross; J M Goldman
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

5.  Epstein-Barr virus-negative Hodgkin's lymphoma after mycosis fungoides: molecular evidence for distinct clonal origin.

Authors:  M Kremer; M Sandherr; B Geist; A D Cabras; H Höfler; F Fend
Journal:  Mod Pathol       Date:  2001-02       Impact factor: 7.842

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples from chronic myelogenous leukemia patients.

Authors:  K A Kreuzer; U Lass; S Nagel; H Ellerbrok; G Pauli; B Pawlaczyk-Peter; W Siegert; D Huhn; C A Schmidt
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

8.  Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.

Authors:  Marcia L Taylor; Devinder Sehgal; Mark Raffeld; Harold Obiakor; Cem Akin; Rose G Mage; Dean D Metcalfe
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

9.  Molecular detection of bone marrow involvement in intravascular lymphomatosis.

Authors:  J A DiGiuseppe; D P Hartmann; C Freter; J Cossman; R B Mann
Journal:  Mod Pathol       Date:  1997-01       Impact factor: 7.842

10.  From genes to therapy: the case of Philadelphia chromosome-positive leukemias.

Authors:  Daniela Cilloni; Aagelo Guerrasio; Emilia Giugliano; Patrizia Scaravaglio; Gisella Volpe; Giovanna Rege-Cambrin; Giuseppe Saglio
Journal:  Ann N Y Acad Sci       Date:  2002-06       Impact factor: 5.691

View more
  4 in total

Review 1.  Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.

Authors:  K N Naresh; I Lampert; R Hasserjian; D Lykidis; K Elderfield; D Horncastle; N Smith; W Murray-Brown; G W Stamp
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.

Authors:  Thomas Horn; Marcus Kremer; Tobias Dechow; Walther M Pfeifer; Birgit Geist; Michael Perker; Justus Duyster; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

Review 3.  [Bone marrow biopsy: processing and use of molecular techniques].

Authors:  L Quintanilla-Martinez; M Tinguely; I Bonzheim; F Fend
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

4.  How we do: optimizing bone marrow biopsy logistics for sign-out within 2 days.

Authors:  I de Laak-de Vries; A G Siebers; L Burgers; C Diepenbroek; M Link; P Groenen; J H J M van Krieken; K M Hebeda
Journal:  J Hematop       Date:  2016-03-05       Impact factor: 0.196

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.